Pharsight

Synjardy generic

Synjardy is an anti-diabetic drug owned by Boehringer Ingelheim. The drug, which contains Empagliflozin and Metformin Hydrochloride, was first authorized for market use on 26 August, 2015.

When will Synjardy generic be available?

The generic version of Synjardy is likely to be released after 17 November, 2034, following the expiration of the last of its 12 drug patents.

Synjardy uses

Synjardy is used for treating type 2 diabetes mellitus in patients with renal impairment. It reduces the risk of cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes mellitus through a once-daily administration of Empagliflozin. Furthermore, it is used to treat type 2 diabetes mellitus in a patient with renal impairment by the once-daily administration of 10 mg or 25 mg of Empagliflozin.

Synjardy patent expiration

Synjardy has a total of 12 drug patents, none of which have expired. The last patent is set to expire on 17 November, 2034. Below are the details of the patent:

EPO Oppostions filed on Synjardy

Synjardy dosage

Want to ask something?